Business Context and Reporting Period
This summary covers the Form 10-Q filed by Diebold, Incorporated (now Diebold Nixdorf, Inc.) for the quarterly period ended June 30, 2001. The company operates in three primary segments: Diebold North America (DNA), Diebold International (DI), and Other. The financial statements are unaudited and reflect a corporate-wide realignment program initiated in the first quarter of 2001.
Key Financial Metrics
| Metric | Q2 2001 | Q2 2000 | YTD 2001 | YTD 2000 |
|---|---|---|---|---|
| Net Sales | $423.6 million | $442.1 million | $807.5 million | $786.7 million |
| Gross Profit | $133.0 million | $142.2 million | $250.2 million | $259.0 million |
| Operating Profit | $46.2 million | $61.7 million | $59.8 million | $110.9 million |
| Net Income | $27.8 million | $35.8 million | $35.3 million | $67.1 million |
| Diluted EPS | $0.39 | $0.50 | $0.49 | $0.94 |
| Cash from Operations (YTD) | $100.1 million (2001) vs $16.4 million (2000) | |||
| Cash & Equivalents | $34.9 million (June 30, 2001) | |||
| Notes Payable | $159.7 million (June 30, 2001) |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2001 net sales decreased 4.2% compared to Q2 2000. This decline is primarily attributed to the absence of non-recurring voting machine revenue ($41.5 million) recognized in Q2 2000. Excluding this item, sales increased 5.7% due to an expanded international customer base.
- Profitability Impact: Net income for Q2 2001 fell 22.4% year-over-year. The decrease is driven by realignment and special charges of $6.2 million (after-tax) in the quarter and $24.3 million (after-tax) year-to-date.
- Segment Performance:
- Diebold North America (DNA): Operating profit dropped 27.5% in Q2 and 45.7% YTD, largely due to realignment charges and a weak U.S. market.
- Diebold International (DI): Operating profit decreased 18.6% in Q2 and 40.3% YTD. However, excluding voting machine revenue from the prior year, DI revenues grew significantly (13.4% in Q2, 29.2% YTD), driven by acquisitions and growth in Europe, the Middle East, and Africa.
- Balance Sheet: Total assets decreased 3.3% to $1.53 billion, primarily due to the securitization of finance receivables and foreign currency impacts on goodwill. Inventory increased 12.2% to meet international demand.
Guidance, Outlook, and Risks
- Outlook: Management anticipates stronger second-half results due to cost actions and an expanded global infrastructure.
- Q3 2001 EPS Guidance: $0.46 to $0.51 (excluding realignment and special charges).
- Full Year 2001 EPS Guidance: $1.95 to $2.00 (excluding realignment, special charges, and MedSelect operating losses).
- Remaining Charges: Estimated additional realignment and special charges of $20 million to $30 million for the remainder of 2001.
- Realignment Program: A corporate-wide program initiated in Q1 2001 aims to generate approximately $25 million in annual savings. Approximately 470 jobs have been eliminated as of June 30, 2001.
- Accounting Changes: The company is adopting SFAS No. 141 and 142 regarding business combinations and goodwill. Goodwill will no longer be amortized but tested for impairment annually starting Jan 1, 2002. The impact of transitional impairment losses is currently not estimable.
- Risks: Key risks include foreign currency fluctuations (specifically the Brazilian Real), competitive pricing pressures, and the ability to generate revenue growth in domestic and international markets.
Investor Verification Checklist
- Realignment Costs: Verify the timing and magnitude of the remaining $20–$30 million in restructuring charges expected for the rest of 2001.
- International Growth: Confirm the sustainability of revenue growth in the Diebold International segment, particularly in Europe and the Middle East, excluding one-time prior-year voting machine sales.
- Currency Exposure: Assess the impact of the weakening Brazilian Real on future earnings and comprehensive income.
- Goodwill Impairment: Monitor the upcoming adoption of SFAS 142 for potential transitional impairment losses on the $205.4 million of unamortized goodwill.
- MedSelect Divestiture: Review the status of the MedSelect sale and its impact on the "Other" segment's operating losses.